MannKind Corporation

MNKD

Net income
-86.1
millions, $
Market cap
1.05
billions, $
EBITDA
-31.2
millions, $
Revenue
74.5
millions, $
P/E
N/A
Revenue Growth
20
% year on year
Dividends

Estimation

0
% per year
About

MannKind Corporation is a biopharmaceutical company that is committed to the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases.

MannKind Corporation

1. There may be a delay in updating the share price

The information on Dastocks.com is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy, or in any other way. Dastocks will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on the information on Dastocks.com. The Authors may buy and sell securities before and after any particular article and/or information herein is published.

You must accept the terms and conditions if you wish to continue to use the Dastocks website.